Allergan Aesthetics to Acquire Soliton for $22.60 per Share
09:03 AM EDT, 05/10/2021 (MT Newswires) -- Allergan Aesthetics, an AbbVie (ABBV) company, and Soliton (SOLY) said Monday they signed an agreement for Allergan to acquire Soliton, along with Resonic, its rapid acoustic pulse device, for $22.60 per share in cash.
Soliton's enterprise value for the transaction is around $550 million.
Resonic, which recently received the US Food and Drug Administration's clearance, is a noninvasive treatment for the short-term improvement in the appearance of cellulite.
The transaction is subject to customary closing conditions, including clearance by the US antitrust authorities under the Hart-Scott-Rodino Act and approval of Soliton's shareholders.
Price: 116.14, Change: +0.39, Percent Change: +0.34